Sprint Bioscience is a Swedish biotechnology company specializing in the development of innovative oncology drug candidates using a fragment-based drug discovery approach. Their business model focuses on preclinical development and licensing of drug programs to global pharmaceutical companies. The website targets investors, partners, and the scientific community with comprehensive information on their research, pipeline, and investor relations. Technically, the site is built on WordPress with the Bricks builder framework, incorporating modern web technologies and Google Tag Manager for analytics. The site is mobile-optimized and presents a professional design with clear navigation. Security-wise, the site enforces HTTPS and includes a cookie consent mechanism, but lacks published security policies or incident response contacts. No critical vulnerabilities or exposed sensitive data were detected. Overall, the website demonstrates a solid digital presence aligned with the company's business focus, though improvements in security transparency and compliance documentation are recommended.
Scanned ·
NIS2 and GDPR posture
GDPR outside view
40/ 100 · High
Checks completed
7of 7
NIS2 Art. 21(2)
a(a) Risk analysis and security policies: Not visible from outside
b(b) Incident handling: One indicator
c(c) Business continuity, backups and crisis management: Not visible from outside
d(d) Supply chain security: Not visible from outside
e(e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
f(f) Assessing the effectiveness of security measures: Not visible from outside
g(g) Cyber hygiene and security training: Not visible from outside
h(h) Cryptography and encryption: Partly checked
i(i) HR security, access control and asset management: One indicator
j(j) Multi-factor authentication and secured communications: Not visible from outside
Partly checked
One indicator
Not visible from outside
This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.
GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.
Priority findings
8 findings rated critical or high. Fix these first.
GDPR outside view
These are the privacy signals visitors and data protection authorities look for under GDPR.
Critical
No HTTPS encryption
GDPR requires appropriate security measures for personal data
What to do: Implement SSL/TLS certificate for HTTPS
Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.
High
Missing Strict-Transport-Security header
Forces HTTPS connections
What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"
This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.
Daily monitoring
Recommended
€25per month
TLS certificates and expiry
DNS records
SPF, DKIM and DMARC
Security headers
GDPR and NIS2 posture
Exposed services
Third-party trackers
Security score drift
Email alerts on material changes and an exportable JSON history of every change.
Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.
Full report
€39.90one-time
The complete analysis as a PDF you can cite
Email delivery with an unlock code
Lifetime access to this report
Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.
Results by check
Each check with its score, findings and the evidence it collected.
How this score is calculated
The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.
Counted in this score
SSL/TLS
0
Security headers
15
Email security
70
DNS health
85
Network security
20
GDPR outside view
40
Average
38
Not counted
NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.
Findings that cap the score at 49
Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.
The certificate is not trusted by browsers
The website is not served over HTTPS
A database, remote desktop, file-sharing or Telnet service is reachable from the internet
The page loads a script from a compromised source
The domain registration has expired
SPF authorises every server to send mail as the domain
Partial scans
When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.
Risk levels
Critical0–25
High26–49
Medium50–75
Low76–100
Breach exposure
Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.
Dark web exposure
Add-on
Leaked records that mention sprintbioscience.com, from OffSeq Breach.
No leaked records found
Breach holds no records for sprintbioscience.com right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.
Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.
Business context
Business profile
Sprint Bioscience occupies a niche in the oncology biotech sector with a focus on fragment-based drug discovery, which provides a competitive advantage in speed and resource efficiency. Their revenue model is based on licensing preclinical drug candidates to larger pharmaceutical companies, indicating a B2B partnership-driven growth strategy. The company actively communicates with investors through press releases and financial reports, signaling transparency and engagement. Their partnership with SciLifeLab enhances their research capabilities. The target market includes pharmaceutical partners and investors interested in innovative cancer treatments. The company appears to be small-sized with a focused product pipeline and a clear strategic direction.
Security posture
The website demonstrates a moderate to good security posture with HTTPS enforced and a cookie consent banner that complies with GDPR requirements. However, there is no visible security policy or incident response information, which are important for transparency and trust. Security headers are not explicitly detected, and no vulnerability disclosure or security.txt files are present. No exposed sensitive data or vulnerable libraries were found in the HTML content. The absence of explicit security documentation and incident contacts represents a compliance gap and an area for improvement. Overall, the security posture is adequate but could be enhanced by publishing formal policies and improving header configurations.
Recommendations
Publish a dedicated security policy page outlining security practices and compliance.
Add incident response contact information such as security@ or abuse@ email addresses.
Implement a vulnerability disclosure policy or security.txt file to encourage responsible reporting.
Enhance HTTP security headers including Content-Security-Policy, X-Content-Type-Options, and X-Frame-Options.
Improve accessibility features to meet higher compliance standards and broaden user inclusivity.
Automated reading of the public site. Ratings are indicative.
Business
Company
Sprint Bioscience
Description
Sprint Bioscience är ett läkemedelsbolag med fokus på att utveckla innovativa läkemedelskandidater som kan bidra till nya behandlingsformer för cancer. De använder en fragmentbaserad läkemedelsutvecklingsmetod för att utveckla läkemedelsprogram som licensieras till globala läkemedelsbolag under preklinisk fas.
Key services
Forskning och utveckling av onkologiska läkemedelskandidater, Licensiering av läkemedelsprogram till globala läkemedelsbolag
Content quality
good
Branding
consistent
Technology
Stack
WordPress, Bricks Builder, Google Tag Manager, MFN News Feed Widget, SVGInject
Frameworks
Bricks
Platforms
WordPress
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good
Security
Observed score
85/100
Good practices seen
HTTPS enforced
Cookie consent banner with consent mechanism
No exposed sensitive data in HTML
Analytics and tracking
Services
Google Analytics
Tracking level
moderate
Privacy practices
good
Advertising
Tracking pixels
Google Analytics (via Google Tag Manager)
Transparency
basic
Site quality
Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high
Key observations
Website is fully accessible with no blocking or WAF challenges.
Content is primarily in Swedish with English alternate language available.
Strong focus on oncology drug development and investor relations.
Cookie consent mechanism is implemented and visible.
No explicit terms of service page found.
No explicit security or incident response policies published.
Contact information includes phone and physical address but no email contact found on main page.
Use of modern web technologies and CMS (WordPress with Bricks builder).
Google Tag Manager used for analytics and tracking.
No exposed sensitive data or obvious vulnerabilities detected in HTML content.
Technical notes
Notes
The website is built on WordPress CMS using the Bricks builder framework, which supports modern web development practices. It uses Google Tag Manager for analytics and tracking, and SVGInject for SVG image handling. The site loads multiple optimized CSS and JS files, indicating performance considerations. Mobile optimization is good, and SEO meta tags including Open Graph and Twitter cards are properly implemented. No major technical debt or outdated libraries were detected. Hosting provider details are not explicit, but the site uses HTTPS with valid certificates. Performance is moderate, with room for improvement in loading speed and accessibility compliance.
Standards and sources
Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.
Reviews of this site
Share your experience with sprintbioscience.com. Every review is verified by email and published after moderation.
Community rating
No published reviews yet. Be the first to review sprintbioscience.com.